The role of BTA stat in clinical practice

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 2, 2002, Pages 212-216

  Quek, Pearllyn ^a   Chin, C M ^b   Lim, P H C ^b  

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b NONE

Author keywords

Bladder tumour markers; BTA stat; Voided urine cytology

Indexed keywords

BLADDER TUMOR ASSOCIATED ANTIGEN; BLADDER TUMOR-ASSOCIATED ANTIGEN; DIAGNOSTIC AGENT; TUMOR ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER TUMOR; CYTOLOGY; EVALUATION; FEMALE; HEMATURIA; HUMAN; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; URINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 0036519216     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sharma S, Zippe C D, Pandranji L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162:53-7.
2. Gutierrez Banos J L, Martin Garcia B, de Diego Rodriguez E, Hernandez Rodriguez R, Portillo Martin JA, Correas Gomez M A, et al. The BTA stat test in the follow up for bladder cancer. Arch Esp Urol 1999; 52: 56-61.
3. Paez A, Coba J M, Murillo N, Fernandez P, de la Cal M A, Lujan M, et al. Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol 1999; 35:228-32.
4. Sharkey F E, Sarosdy M F. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ. J Urol 1997; 157:68-72.
5. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158:2098-101.
6. Schmetter B S, Habicht K K, Lamm D L, Morales A, Bander N H, Grossman H B, et al. A multicenter trial evaluation of the fibrin/ fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158:801-5.
7. Stampfer D S, Carpinito G A, Rodriguez-Villanueva J, Willsey L W, Dinney C P, Grossman H B, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159:394-8.
8. Ramakumar S, Bhuiyan J, Besse J A, Roberts S G, Wollan P C, Blute M, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 61:388-94.
9. Gutierrez Banos J L, Rebollo Rodrigo M H, Antolin Juarez F, Martin Garcia B, Hernandez Rodriuez R, Portillo Martin J A, et al. Comparative study of BTA stat test. NMP 22 and cytology in the diagnosis of bladder cancer. Arch Esp Urol 2000; 53:21-7.
10. Giannopoulos A, Manousakas T, Mitropoulos D, Botsoli-Stergiou E, Constantinides C, Giannopoulos M, et al. Comparative evaluation of the BTA stat test, NMP22 and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 2000; 55:871-5.
11. Lokeshwar V B, Obek C, Pham H T, Wei D, Young M J, Duncan R C, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163:348-56.
12. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000; 56:228-31.
13. Sarosdy M F, Hudson M A, Ellis W J, Soloway M S, deVere White R, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997; 50:349-53.
14. Halachmi S, Linn J F, Amiel G E, Moskovitz B, Nativ O. Urine cytology, tumour markers and bladder cancer. Br J Urol 1998; 82:647-54.
15. Planz B, Striepecke E, Jakse G, Bocking A. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma. J Urol 1998; 159: 384-8.
16. Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159:389-93.
17. Wiener H G, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998; 59:1876-80.
18. Badalament R A, Hermansen D K, Kimmel M, Gay H, Herr H W, Fair W R, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma. Cancer 1987; 60:1423-7.
19. Raitenen M P, Martilla T, Kaasinen E, Rintal E, Aine R, Tammela T L. Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 2000; 163:1689-92.
20. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Non-invasive detection of bladder cancer with the BTA stat test. J Urol 1999; 161:443-6.
21. Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, et al. Comparison of BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35:52-6.
22. Gutierrez Banos J L, Martin Garcia B, Hernandez Rodriguez R, Portillo Martin J A, Correas Gomez M A, del Valle Schaan J L, et al. Usefulness of BTA stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy. Arch Esp Urol 1998; 51:778-82.
23. Khadra M H, Pickard R S, Charlton M, Powell P H, Neal D E. Messing E M. A prospective analysis of 1,930 patients with haematuria to evaluate current diagnostic practice. J Urol 2000; 163:524-31.
24. Raitenen M P, Tammela T L. Specificity of human complement factor H related protein test (Bard BTA stat Test). Scand J Urol Nephrol 1999; 33:234-6.